| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.15 | 5e-06 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.13 | 7e-05 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0003 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0004 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.17 | 0.0004 |
| mRNA | Panobinostat | FIMM | pan-cancer | AAC | -0.41 | 0.001 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.003 |